Skip to Content

Cubist Systematic Strategies LLC acquires 14,768 Omnicell, Inc. shares (NASDAQ:OMCL)

Cubist Systematic Strategies LLC acquires 14,768 Omnicell, Inc. shares (NASDAQ:OMCL)

The most recent 13F filing that the company has submitted to the SEC reveals that during the third quarter, Cubist Systematic Strategies LLC increased its holdings in Omnicell, Inc. (NASDAQ: OMCL) by 152.3%. The corporation has a total of 24,463 shares of ownership in the company after purchasing an additional 14,768 shares of the company’s stock during the quarter. This brings the total number of shares to 24,463. After the most recent fiscal quarter, Cubist Systematic Strategies LLC owned approximately 0.06% of Omnicell, which had a value of $2,129,000.

There have also been transactions involving hedge funds and various other institutional investors involving buying and selling OMCL shares. During the third quarter, Guggenheim Capital LLC achieved a 168.5% increase in the proportion of Omnicell stock it owned. Guggenheim Capital LLC now holds 7,659 shares of the company’s stock, which has a value of $667,000. This is due to acquiring an additional 4,807 shares during the most recent fiscal quarter. In the third quarter, Verition Fund Management LLC made a fresh investment in Omnicell. The total value of this investment was close to $227,000. During the third quarter, Lazard Asset Management LLC completed a 24.1% increase in the Omnicell stock held in its portfolio. Lazard Asset Management LLC now has 1,097,358 shares of the company following the purchase of an additional 212,817 shares during the most recent quarter. The value of Lazard Asset Management LLC’s holdings in the company at the moment is $95,502,000. During the third quarter of the fiscal year, Wrapmanager Inc. bought an additional 85.1% stake in Omnicell, bringing its total ownership to 100%. Following the purchase of an additional 2,385 shares during the most recent quarter, Wrapmanager Inc. now holds a total of 5,188 shares of the company’s stock, which gives the company a market value of $452,000 in its entirety. And finally, but certainly not least, MML Investors Services LLC increased the total amount of Omnicell stock held by 24.0% during the third quarter. During the most recent quarter, MML Investors Services LLC increased its company stock holdings by purchasing 980 additional shares. This brought the total number of shares purchased to 5,066 for $441,000.00.

According to information obtained from a different source regarding Omnicell, Executive Vice President Scott Peter Seidelmann sold 945 shares on Tuesday, December 27. The total number of sold shares resulted in revenue of $45,624.60, which indicates that the average price paid for those shares was $48.28. As a direct result of the transaction, the executive vice president acquired 29,788 company shares, which have a combined value at the current market price of approximately $1,438,164.64. If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission and where the transaction was discussed. You can simply ignore this link if you do not want to follow it. In addition, on December 1, the Chief Executive Officer of Omnicell, Randall A. Lipps, sold 2,500 shares of the company’s stock. It was determined that the price of $50.78 per share was the average price paid for the shares, which resulted in a total of $126,950.00 being acquired from the sale of the shares. Following the successful conclusion of the transaction, the Chief Executive Officer now has direct ownership of 88,348 shares of the company, the total value of which is 4,486,311.44 dollars. If you follow this link, you will be taken to the SEC filing in which the sale was disclosed. Please click on the link to proceed.

On top of that, Executive Vice President Scott Peter Seidelmann sold 945 shares of the company’s stock on Tuesday, December 27. For $48.28 per share, a total of $45,624.60’s worth of the stock was traded, resulting in cash accumulation. The average price of each share was $48.28. Following the successful conclusion of the transaction, the executive vice president was awarded direct ownership of 29,788 shares of the company’s stock. The total value of these shares is $1,438,164.64. Disclosures that are related to the sale might be found in this section of the website. Corporate insiders sold a total of 9,674 shares of stock over the preceding three months, bringing the total value of those sales to $476,839 in total. The company’s management and employees collectively own 2.76% of the company’s total shares of stock.

On Tuesday’s trading session, the price of OMCL shares ended the day at $56.97, reflecting a decrease of $0.09 from the previous day’s closing price. There were a total of 8,427 trades made in the company’s shares, which is a volume that is significantly lower than the company’s average daily volume of 421,881 shares. Its current valuation of $2.52 billion is based on several metrics, including its price-to-earnings ratio of 55.94, its price-to-earnings-to-growth ratio of 5.15, and its beta value of 0.89. These metrics all contribute to the company’s overall value. The simple moving average for the company over the past 50 days is currently at $50.68, and the simple moving average over the past 200 days is currently at $80.38. The debt-to-equity ratio comes in at 0.50, the quick ratio comes in at 1.86, the current ratio comes in at 2.25, and the quick ratio comes in at 1.86. Over the past year, the share price of Omnicell, Inc., has moved in a range that has spanned from $46.11 to $166.12 per share.

On November 2, the most recent earnings report for Omnicell, which is publicly traded and can be found under the symbol NASDAQ: OMCL, was made available to the public. The company announced that it had earnings per share (EPS) of $0.70 for the period, which is $0.04 more than the estimate made by the market, which was $0.66. The company’s most recent quarter’s revenue came in at $348.06 million, which is significantly lower than the consensus projection of $362.72 million in revenue for the quarter. Omnicell had a return on equity of 9.74% and a net margin of 3.67% for the company overall. The current fiscal year of Omnicell, Inc. is expected to result in earnings of $1.62 per share, according to projections made by industry professionals.

There have been several people who specialize in equity research who have provided their opinions about the stock. In a report distributed on November 3, KeyCorp lowered their price objective on Omnicell shares from $130.00 down to $75.00 while also downgrading their “overweight” rating that they had previously assigned to those shares. Benchmark’s previous recommendation of “buy” for Omnicell was changed to a rating of “hold” in a study that was made public on November 3. On November 3, SVB Leerink lowered its price objective for Omnicell shares from $117.00 to $54.00 and assigned the stock a “market perform” rating. The firm also assigned the stock a rating of “neutral.” JPMorgan Chase & Co. lowered their price objective on Omnicell shares from $140.00 to $57.00 and assigned the company a “neutral” rating in a research report published on Friday, November 18. The findings of the study were published. Lastly, BTIG Research lowered their price objective and “buy” rating that they had previously assigned to Omnicell shares from $160.00 to $75.00 in a research note published on November 3. The new price objective is $75.00, and the “buy” rating remains the same. In comparison, four research analysts have given the company a “hold” rating, while five have given the company a “buy” rating. The company has been given an average recommendation of “Moderate Buy,” and the consensus price objective has been set at $82.11, according to data that Bloomberg provided.

Omnicell, Inc. and its subsidiaries make medication management solutions and adherence tools available in pharmacies and healthcare systems in the United States and other countries worldwide. Automated dispensing systems for operating rooms that are part of the XT Series; automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital that are part of the XT Series; the Omnicell Interface Software, which provides interface and integration between its medication-use products or supply products and a healthcare system; and automated dispensing systems for operating rooms that are part of the XT Series.

Tags

Leave a comment

Your email address will not be published. Required fields are marked *